Compare

Option Care Health/$OPCH

1D1W1M3M6MYTD1Y5YMAX

About Option Care Health

Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
Ticker
$OPCH
Sector
Health
Primary listing
NASDAQ
Employees
7,397

OPCH Metrics

BasicAdvanced
$4.8B
22.95
$1.38
0.46
-

What the Analysts think about OPCH

Analyst ratings (Buy, Hold, Sell) for Option Care Health stock.
Analyst projections of the future price of Option Care Health stock.

Bulls say / Bears say

CD&R and McKesson have agreed to buy Option Care for $32.05 per share in cash, a 37% premium to the 5 October closing price. If shareholders and regulators approve the deal, it gives investors a defined cash exit. (Option Care Health, Inc.)
Second-quarter adjusted EBITDA rose 3% and adjusted EPS rose 12.9% year on year, while operating cash flow reached $184 million. The results suggest operations improved after a weaker first quarter. (Option Care Health, Inc.)
The acute therapy portfolio grew at a high-single-digit rate in the second quarter, while IG/neuro and rare-and-orphan therapies also grew. These areas offer growth beyond the weaker chronic inflammatory portfolio. (U.S. Securities and Exchange Commission)
Management expects chronic inflammatory disease headwinds to reduce 2026 revenue growth by about six percentage points and gross profit by $55 million. Patient attrition and a less favourable therapy mix make a near-term recovery uncertain. (Option Care Health, Inc.)
Revenue grew only 1.6% in the first half, while gross profit fell from a year earlier. Deutsche Bank also questioned whether cost cuts can compensate for weak underlying gross-profit growth. (U.S. Securities and Exchange Commission, Investing.com)
Insurance and formulary changes doubled the number of patients needing benefit rechecks and reauthorisation in the first quarter, delaying decisions and worsening retention. Such payer-driven disruptions could continue to unsettle patient volumes. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

OPCH Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

OPCH Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.